{ "module": "kr-companies", "itemId": "01965324", "title": "SAMSUNG EPIS HOLDINGS Co., Ltd. (삼성에피스홀딩스(주)) — KOSPI 0126Z0", "summary": "Korean listed company (삼성에피스홀딩스(주), KOSPI 0126Z0). Official DART corporate profile, KRW financial summary, and recent filings.", "data": { "corp_code": "01965324", "stock_code": "0126Z0", "name_en": "SAMSUNG EPIS HOLDINGS Co., Ltd.", "name_ko": "삼성에피스홀딩스(주)", "alternate_names": [ "삼성에피스홀딩스" ], "market": "KOSPI", "ceo_name": "김경아", "business_registration_no": "7598803316", "corporate_registration_no": "1201110149508", "address": "인천광역시 연수구 송도교육로 76 삼성에피스홀딩스", "homepage": "https://www.samsungepisholdings.com/", "established_date": "2025-11-03", "fiscal_month": "12", "industry_code": "64992", "financials": { "fiscal_year": 2025, "basis": "CFS", "currency": "KRW", "revenue": 251689950548, "operating_income": -63640615999, "net_income": 85313155522, "total_assets": 7715584325302, "total_liabilities": 1809815283137, "total_equity": 5905769042165, "prior_year": { "fiscal_year": 2024, "revenue": null, "operating_income": null, "net_income": null, "total_assets": null, "total_liabilities": null, "total_equity": null }, "source_url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515003119", "verified_at": "2026-11-01T02:28:18.743Z" }, "recent_filings": [ { "receipt_no": "20261030801097", "filed_date": "2026-10-30", "title_ko": "투자판단관련주요경영사항(자회사의 주요경영사항) (SB27(Keytruda 바이오시밀러) 미국 품목허가 신청)", "title_en": "Material Business Matters Related to Investment Decisions(Subsidiary's material business matters) (SB27(Keytruda 바이오시밀러) 미국 품목허가 신청)", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261030801097" }, { "receipt_no": "20261028800403", "filed_date": "2026-10-28", "title_ko": "연결재무제표기준영업(잠정)실적(공정공시)", "title_en": "Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261028800403" }, { "receipt_no": "20261028800401", "filed_date": "2026-10-28", "title_ko": "연결재무제표기준영업(잠정)실적(공정공시)(자회사의 주요경영사항)", "title_en": "Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)(Subsidiary's material business matters)", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261028800401" }, { "receipt_no": "20261021800142", "filed_date": "2026-10-21", "title_ko": "풍문또는보도에대한해명(미확정)(자회사의 주요경영사항)", "title_en": "Response to Rumors or Media Reports: Undetermined(Subsidiary's material business matters)", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261021800142" }, { "receipt_no": "20261014800360", "filed_date": "2026-10-14", "title_ko": "결산실적공시예고(안내공시)", "title_en": "Prior Notice on Disclosure of Final Earnings", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261014800360" }, { "receipt_no": "20261006800422", "filed_date": "2026-10-06", "title_ko": "최대주주등소유주식변동신고서", "title_en": "Report on Shares Change of Largest Shareholders", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261006800422" }, { "receipt_no": "20261001800667", "filed_date": "2026-10-01", "title_ko": "투자판단관련주요경영사항(자회사의 주요경영사항) (중증 호산구 천식 치료제 SB41(Fasenra 바이오시밀러) 및 유전성 재발열 증후군 치료제 SB44(Ilaris 바이오시밀러) 파트너십 계약 체결)", "title_en": "Material Business Matters Related to Investment Decisions(Subsidiary's material business matters) (중증 호산구 천식 치료제 SB41(Fasenra 바이오시밀러) 및 유전성 재발열 증후군 치료제 SB44(Ilaris 바이오시밀러) 파트너십 계약 체결)", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261001800667" }, { "receipt_no": "20260928800466", "filed_date": "2026-09-28", "title_ko": "[기재정정]기업지배구조보고서공시", "title_en": "[Corrected description]Details of Corporate Governance Report", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260928800466" }, { "receipt_no": "20260907800490", "filed_date": "2026-09-07", "title_ko": "최대주주등소유주식변동신고서", "title_en": "Report on Shares Change of Largest Shareholders", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260907800490" }, { "receipt_no": "20260831000441", "filed_date": "2026-08-31", "title_ko": "대규모기업집단현황공시[분기별공시(개별회사용)]", "title_en": "Disclosure of Current Status of Large-scale Business Groups [Quarterly Disclosure (For individual company)]", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260831000441" }, { "receipt_no": "20260814002990", "filed_date": "2026-08-14", "title_ko": "반기보고서 (2026.06)", "title_en": "Semi-annual Report (2026.06)", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260814002990" }, { "receipt_no": "20260814000262", "filed_date": "2026-08-14", "title_ko": "지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항", "title_en": "Matters concerning payment amount for each payment method-payment period and Dispute Resolution Organization", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260814000262" }, { "receipt_no": "20260810800530", "filed_date": "2026-08-10", "title_ko": "투자판단관련주요경영사항(자회사의 주요경영사항) (SB27주(펨브롤리주맙 바이오시밀러) 한국 품목허가 신청)", "title_en": "Material Business Matters Related to Investment Decisions(Subsidiary's material business matters) (SB27주(펨브롤리주맙 바이오시밀러) 한국 품목허가 신청)", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260810800530" }, { "receipt_no": "20260804800465", "filed_date": "2026-08-04", "title_ko": "최대주주등소유주식변동신고서", "title_en": "Report on Shares Change of Largest Shareholders", "filer": "삼성에피스홀딩스", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260804800465" }, { "receipt_no": "20260804000330", "filed_date": "2026-08-04", "title_ko": "임원ㆍ주요주주특정증권등소유상황보고서", "title_en": "Report on status of specific securities, etc. owned by executives and major shareholders", "filer": "김형준", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260804000330" }, { "receipt_no": "20260804000327", "filed_date": "2026-08-04", "title_ko": "임원ㆍ주요주주특정증권등소유상황보고서", "title_en": "Report on status of specific securities, etc. owned by executives and major shareholders", "filer": "KIM KYUNG-AH", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260804000327" } ], "source_urls": { "company": "https://dart.fss.or.kr", "financials": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515003119", "filings": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261030801097" }, "source_url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515003119", "verified_at": "2026-11-01T02:28:05.338Z", "notice": "Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company." }, "source_url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515003119", "verified_at": "2026-11-01T02:28:05.338Z", "updated_at": "2026-11-01T02:28:05.338Z", "notice": "Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company." }